<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04148183</url>
  </required_header>
  <id_info>
    <org_study_id>Ucol-1</org_study_id>
    <nct_id>NCT04148183</nct_id>
  </id_info>
  <brief_title>Effect of Metformin and Rosiglitazone Over no Diabetic With Metabolic Syndrome Patients.</brief_title>
  <official_title>Randomized Clinical Trial, Effect of Metformin and Rosiglitazone Over Glucose Homeoastasis in no Diabetic With Metabolic Syndrome Patients.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>J JESUS VENEGAS, MD</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Instituto Mexicano del Seguro Social</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Council of Science and Technology, Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Universidad de Colima</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the effect of insulin sensitizing drugs (metformin and rosiglitazone) over glucose
      homeostasis (GH) in no diabetic metabolic syndrome individuals. A randomized blinded clinical
      trial did in patients with metabolic syndrome (n=30), without diabetes. Prior to detailed
      information and signature of informed consent by patients were done three treatment groups by
      randomized technique; a) Placebo, b) Metformin (850 mg/day), c) Rosiglitazone (4 mg/day),
      treatment was administered for 8 weeks. GH was measured before and after treatment using oral
      glucose tolerance test (OGTT), and IR-index (Homeostatic Model). Determination was performed
      on weight, size, body mass index, plicometry, blood pressure, fasting glucose levels,
      triglycerides, HDL-cholesterol and insulin.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Metabolic syndrome is a risk factor for diabetes mellitus characterized by insulin
      resistance, hypertension, triglyceride elevation, low levels of high-density lipoproteins,
      and obesity. Metformin and rosiglitazone are two insulinosensensitizers used in the treatment
      of diabetes. Now there is controversy over the use of insulinossensitizers in non-diabetic
      patients with metabolic syndrome. To compare the effect of insulin sensitizing drugs
      (metformin and rosiglitazone) over glucose homeostasis (GH) in no diabetic metabolic syndrome
      individuals. Randomized blinded clinical trial in patients with metabolic syndrome without
      diabetes was done, sample size (n=30). Prior to detailed information and signature of
      informed consent by patients was randomized forming three treatment groups, a) Placebo, b)
      Metformin (850 mg/day), c) Rosiglitazone (4 mg/day), treatment was administered for 8 weeks.
      GH was measured before and after treatment using oral glucose tolerance test (OGTT), and
      IR-index (Homeostatic Model). Determination was performed on weight, size, body mass index,
      plicometry, blood pressure, fasting glucose levels, triglycerides, HDL-cholesterol and
      insulin. Statistic no parametric (Kruskal Wallis, Wilcoxon, U Mann Whitney) to compare
      characteristics inter o intra groups was done. Exact Fisher test was used for qualitative
      variable, and consider significance with p&lt;0.05.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2004</start_date>
  <completion_date type="Actual">January 1, 2009</completion_date>
  <primary_completion_date type="Actual">January 1, 2005</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prior to detailed information and signature of informed consent by patients, it was randomized forming three treatment groups, a) Placebo, b) Metformin (850 mg/day), c) Rosiglitazone (4 mg/day), treatment was administered for 8 weeks</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>INSULIN RESISTANCE</measure>
    <time_frame>8 weeks</time_frame>
    <description>INSULIN RESISTANCE index (Homeostatic Model) is method that need insulin concentration and glucose in blood to calculate index.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>oral glucose tolerance test (OGTT),</measure>
    <time_frame>8 weeks</time_frame>
    <description>oral glucose tolerance test was done take a sample of blood before a period without feed of 8 hours, we took a blood glucose sample then we gave a 75g of glucose and after we took blood glucose at the hour and 2 hours of OGTT test</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Insulin Resistance</condition>
  <arm_group>
    <arm_group_label>Metformin Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Metformin (850 mg/day) treatment was administered for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Rosiglitazone Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Rosiglitazone (4 mg/day), treatment was administered for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo treatment was administered for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin group</intervention_name>
    <description>We add treatment with Metformin (850 mg/day), treatment was administered for 8 weeks</description>
    <arm_group_label>Metformin Group</arm_group_label>
    <other_name>Metformina</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rosiglitazone group</intervention_name>
    <description>we add Rosiglitazone (4 mg/day), treatment was administered for 8 weeks</description>
    <arm_group_label>Rosiglitazone Group</arm_group_label>
    <other_name>Rosiglitazona</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>We add Placebo, treatment was administered for 8 weeks</description>
    <arm_group_label>Placebo Group</arm_group_label>
    <other_name>Control Group</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  &gt; 18 years old.

          -  Metabolic Syndrome criteria of World Health Organization .

        Exclusion Criteria:

          -  Diabetes Mellitus

          -  Allergic to Metformin,

          -  Allergic to rosiglitazone.

          -  Hepatic disease.

          -  Hearth disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Carlos Tene, DS</last_name>
    <role>Study Director</role>
    <affiliation>Universidad de Colima</affiliation>
  </overall_official>
  <reference>
    <citation>Seufert J, Lübben G, Dietrich K, Bates PC. A comparison of the effects of thiazolidinediones and metformin on metabolic control in patients with type 2 diabetes mellitus. Clin Ther. 2004 Jun;26(6):805-18. Review.</citation>
    <PMID>15262452</PMID>
  </reference>
  <reference>
    <citation>Gulias-Herrero A, Aguilar-Salinas CA, Gómez-Pérez FJ, Rull JA. The combination metformin/glyburide exerts its hypoglycemic effect mainly by increasing insulin secretion: a controlled, randomized, double-blind, crossover study. Diabetes Nutr Metab. 2003 Oct-Dec;16(5-6):268-76.</citation>
    <PMID>15000437</PMID>
  </reference>
  <reference>
    <citation>Davidson MB. Is treatment of insulin resistance beneficial independent of glycemia? Diabetes Care. 2003 Nov;26(11):3184-6. Review.</citation>
    <PMID>14578261</PMID>
  </reference>
  <reference>
    <citation>Lehtovirta M, Forsén B, Gullström M, Häggblom M, Eriksson JG, Taskinen MR, Groop L. Metabolic effects of metformin in patients with impaired glucose tolerance. Diabet Med. 2001 Jul;18(7):578-83.</citation>
    <PMID>11553189</PMID>
  </reference>
  <reference>
    <citation>Derosa G, D'Angelo A, Ragonesi PD, Ciccarelli L, Piccinni MN, Pricolo F, Salvadeo SA, Montagna L, Gravina A, Ferrari I, Paniga S, Cicero AF. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. Intern Med J. 2007 Feb;37(2):79-86.</citation>
    <PMID>17229249</PMID>
  </reference>
  <reference>
    <citation>Mohiyiddeen L, Watson AJ, Apostolopoulos NV, Berry R, Alexandraki KI, Jude EB. Effects of low-dose metformin and rosiglitazone on biochemical, clinical, metabolic and biophysical outcomes in polycystic ovary syndrome. J Obstet Gynaecol. 2013 Feb;33(2):165-70. doi: 10.3109/01443615.2012.745839.</citation>
    <PMID>23445141</PMID>
  </reference>
  <verification_date>October 2019</verification_date>
  <study_first_submitted>October 29, 2019</study_first_submitted>
  <study_first_submitted_qc>October 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">November 1, 2019</study_first_posted>
  <last_update_submitted>October 31, 2019</last_update_submitted>
  <last_update_submitted_qc>October 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">November 5, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Universidad de Colima</investigator_affiliation>
    <investigator_full_name>J JESUS VENEGAS, MD</investigator_full_name>
    <investigator_title>Master Degree, Nephrologist</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Rosiglitazone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

